Trial reportThe oncologist2025
Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.
Trial report in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03796364 (Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRadiation pneumonitis (RP) is a common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The treatment of RP needs to be improved.
methodsNSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.
resultsA total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs 1.47 months, P = .048). The RP mortality rate was 5% and 35% in the Rh-endostatin group and control group, respectively (P = .044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25% vs 45%, P = .185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 and 6.0 months, respectively (hazard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.40-2.23, P = .910). The median overall survival was 16.0 and 7.7 months in two groups, respectively (HR: 0.56, 95%CI: 0.27-1.16, P = .119). There was no significant difference between the two groups in adverse events.
conclusionThis prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients. DISCUSSION: This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.ClinicalTrials.gov Identifier: NCT03796364. CLINICALTRIALS.GOV IDENTIFIER: NCT03796364.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.